Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban versus aspirin to prevent stroke in atrial fibrillation patients unsuitable for vitamin K antagonists
2007-001557-26Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apixaban in Atrial fibrillation (AFib) and systemic embolism (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Composite outcome of stroke or systemic embolism. Started Oct 2007; status: completed.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)systemic embolism
Beyond the preview
Go deeper on 2007-001557-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001557-26.